SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Singh Manish

(Last)

(First)

(Middle)

21900 BURBANK BOULEVARD, 3RD FLOOR

(Street)

WOODLAND HILLS

91367

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
05/25/2012

3. Issuer Name and Ticker or Trading Symbol
ImmunoCellular Therapeutics, Ltd. [ IMUC ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & CEO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	907,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽¹⁾	09/28/2015	Common Stock	25,000	$0.27	D
Stock Option (right to buy)	⁽²⁾	09/13/2016	Common Stock	1,384	$0.95	D
Stock Option (right to buy)	⁽²⁾	09/13/2016	Common Stock	30,000	$0.95	D
Stock Option (right to buy)	⁽³⁾	02/17/2017	Common Stock	510,000	$0.9	D
Stock Option (right to buy)	⁽⁴⁾	09/26/2017	Common Stock	30,000	$0.9	D
Stock Option (right to buy)	⁽⁵⁾	02/17/2018	Common Stock	270,000	$2.25	D
Warrant (right to buy)	01/13/2012	01/12/2017	Common Stock	50,000	$1.41	D

Explanation of Responses:

1. The option vested in four equal quarterly installments following September 29, 2008.

2. The option vested in four equal quarterly installments following September 14, 2009.

3. The option vested in equal monthly installments following February 18, 2010.

4. The option vested in four equal quarterly installments following September 27, 2010.

5. The option vested as to 20,000 shares on February 17, 2012, will vest as to 50,000 shares on each of February 17, 2013 and February 17, 2014, and will vest as to 150,000 shares upon achieving certain milestones.

	/s/ Manish Singh	05/25/2012
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.